| Code | CSB-RA624104MB13HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to ZL-1102, targeting interleukin-17A (IL-17A), a pro-inflammatory cytokine that plays a central role in immune-mediated inflammatory responses. IL-17A is primarily produced by T helper 17 (Th17) cells and serves as a key mediator in host defense against extracellular pathogens. However, dysregulated IL-17A signaling contributes to the pathogenesis of numerous autoimmune and inflammatory conditions, including psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease. By neutralizing IL-17A, this antibody helps elucidate the cytokine's involvement in inflammatory cascades and tissue damage mechanisms.
ZL-1102 represents a therapeutic antibody designed to block IL-17A activity, making this biosimilar a valuable tool for investigating IL-17A-mediated pathways in disease models. Researchers can utilize this antibody to study the molecular mechanisms underlying Th17-driven inflammation, evaluate potential therapeutic interventions, and explore biomarker development in autoimmune disease research. The antibody provides a cost-effective alternative for laboratories conducting mechanistic studies of IL-17A biology and inflammatory disease pathogenesis.
There are currently no reviews for this product.